[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fPv85y-Cw0-yG-cAgrARDBmz4GDBlmKcFmDobWnIBK8A":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":50,"rows":57},"Orion Corporation, Orion Pharma",[4],100,false,3,8,9853,6,12,[14,17,20,22,25,28,30,32],{"name":15,"count":16},"Asthma",21,{"name":18,"count":19},"Healthy",18,{"name":21,"count":9},"Parkinson's Disease",{"name":23,"count":24},"Healthy Volunteers",7,{"name":26,"count":27},"Prostate Cancer",5,{"name":29,"count":8},"Amyotrophic Lateral Sclerosis",{"name":31,"count":8},"Healthy Volunteer Study",{"name":33,"count":34},"Alzheimer's Disease",2,[36,41,46],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT03436485","Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer","2026-07-31","ODM-208",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT06725758","A Phase 1\u002F2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours","2027-12-31","ODM-212",{"nctId":47,"briefTitle":48,"date":49,"intervention":45},"NCT07563738","A 2-part Phase 1\u002F2 Open-label Trial on ODM-212","2029-09",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,93,143,161,179,197,215,291,350,418,457,480,505,523,549,567,585,616,634,660,678,696,714,799,832,866,888,906,931,949,976,1001,1026,1044,1070,1088,1115,1133,1151,1169,1194,1250,1291,1335,1367,1395,1425,1458,1485,1513,1535,1557,1579,1610,1632,1654,1676,1698,1720,1746,1768,1790,1814,1839,1857,1880,1898,1916,1934,1959,1977,1995,2013,2036,2059,2080,2103,2121,2139,2157,2175,2193,2211,2229,2252,2274,2292,2314,2332,2350,2375,2398,2424,2442,2460,2484,2502,2520,2538,2561,2579,2604,2627],{"intervention":45,"totalTrials":34,"cells":59},{"EARLY_PHASE1":60,"PHASE1":63,"PHASE2":65,"PHASE3":87,"PHASE4":89,"NA":91},{"trials":61,"activeCount":62},[],0,{"trials":64,"activeCount":62},[],{"trials":66,"activeCount":34,"soonestReadout":44},[67,75],{"nctId":42,"briefTitle":43,"status":68,"phases":69,"primaryCompletion":44,"completion":44,"start":70,"enrollment":71,"conditions":72,"interventions":74},"RECRUITING",[52,53],"2023-10-26",315,[73],"Solid Tumours",[45],{"nctId":47,"briefTitle":48,"status":68,"phases":76,"primaryCompletion":49,"completion":49,"start":77,"enrollment":78,"conditions":79,"interventions":83},[52,53],"2026-03-27",229,[80,81,82],"Mesothelioma","Pancreatic Cancer","NSCLC (Advanced Non-small Cell Lung Cancer)",[45,84,85,86],"Ipilimumab and nivolumab","Gemcitabine and nab-paclitaxel","sotorasib",{"trials":88,"activeCount":62},[],{"trials":90,"activeCount":62},[],{"trials":92,"activeCount":62},[],{"intervention":94,"totalTrials":8,"cells":95},"Midazolam",{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":113,"PHASE3":124,"PHASE4":139,"NA":141},{"trials":97,"activeCount":62},[],{"trials":99,"activeCount":62},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT02432664","Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers","TERMINATED",[52],"2016-04-22","2015-04-14",85,[18],[110,111,112,94],"ODM-108 Part I","ODM-108-Part II","ODM-108 Part III",{"trials":114,"activeCount":123,"soonestReadout":39},[115],{"nctId":37,"briefTitle":38,"status":116,"phases":117,"primaryCompletion":39,"completion":39,"start":118,"enrollment":119,"conditions":120,"interventions":122},"ACTIVE_NOT_RECRUITING",[52,53],"2018-03-19",204,[121],"Prostate Cancer Metastatic",[40,94],1,{"trials":125,"activeCount":62},[126],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},"NCT00481312","Dexmedetomidine Versus Midazolam for Continuous Sedation in the Intensive Care Unit (ICU)","COMPLETED",[54],"2009-08","2009-10","2007-06",501,[136],"Continuous Sedation in Initially Sedated Adults in ICU",[138,94],"Dexmedetomidine",{"trials":140,"activeCount":62},[],{"trials":142,"activeCount":62},[],{"intervention":40,"totalTrials":123,"cells":144},{"EARLY_PHASE1":145,"PHASE1":147,"PHASE2":149,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":146,"activeCount":62},[],{"trials":148,"activeCount":62},[],{"trials":150,"activeCount":123,"soonestReadout":39},[151],{"nctId":37,"briefTitle":38,"status":116,"phases":152,"primaryCompletion":39,"completion":39,"start":118,"enrollment":119,"conditions":153,"interventions":154},[52,53],[121],[40,94],{"trials":156,"activeCount":62},[],{"trials":158,"activeCount":62},[],{"trials":160,"activeCount":62},[],{"intervention":84,"totalTrials":123,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":164,"activeCount":62},[],{"trials":166,"activeCount":62},[],{"trials":168,"activeCount":123,"soonestReadout":49},[169],{"nctId":47,"briefTitle":48,"status":68,"phases":170,"primaryCompletion":49,"completion":49,"start":77,"enrollment":78,"conditions":171,"interventions":172},[52,53],[80,81,82],[45,84,85,86],{"trials":174,"activeCount":62},[],{"trials":176,"activeCount":62},[],{"trials":178,"activeCount":62},[],{"intervention":85,"totalTrials":123,"cells":180},{"EARLY_PHASE1":181,"PHASE1":183,"PHASE2":185,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":182,"activeCount":62},[],{"trials":184,"activeCount":62},[],{"trials":186,"activeCount":123,"soonestReadout":49},[187],{"nctId":47,"briefTitle":48,"status":68,"phases":188,"primaryCompletion":49,"completion":49,"start":77,"enrollment":78,"conditions":189,"interventions":190},[52,53],[80,81,82],[45,84,85,86],{"trials":192,"activeCount":62},[],{"trials":194,"activeCount":62},[],{"trials":196,"activeCount":62},[],{"intervention":86,"totalTrials":123,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":209,"PHASE4":211,"NA":213},{"trials":200,"activeCount":62},[],{"trials":202,"activeCount":62},[],{"trials":204,"activeCount":123,"soonestReadout":49},[205],{"nctId":47,"briefTitle":48,"status":68,"phases":206,"primaryCompletion":49,"completion":49,"start":77,"enrollment":78,"conditions":207,"interventions":208},[52,53],[80,81,82],[45,84,85,86],{"trials":210,"activeCount":62},[],{"trials":212,"activeCount":62},[],{"trials":214,"activeCount":62},[],{"intervention":216,"totalTrials":11,"cells":217},"Levosimendan",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":258,"PHASE4":278,"NA":289},{"trials":219,"activeCount":62},[],{"trials":221,"activeCount":62},[],{"trials":223,"activeCount":62},[224,236,248],{"nctId":225,"briefTitle":226,"status":129,"phases":227,"completion":228,"start":229,"enrollment":230,"conditions":231,"interventions":234},"NCT00130884","Peroral Levosimendan in Chronic Heart Failure",[53],"2006-03","2005-03",300,[232,233],"Chronic Heart Failure","Heart Diseases",[235],"levosimendan",{"nctId":237,"briefTitle":238,"status":129,"phases":239,"primaryCompletion":240,"completion":241,"start":242,"enrollment":243,"conditions":244,"interventions":247},"NCT00698763","Effects of Oral Levosimendan on Ambulatory Electrocardiographic Variables",[53],"2009-04","2009-09","2008-08",32,[245,246],"Transient Ischemic Attack","Stroke",[216],{"nctId":249,"briefTitle":250,"status":129,"phases":251,"completion":252,"start":253,"enrollment":254,"conditions":255,"interventions":257},"NCT00130871","Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass",[53],"2006-01","2004-01",60,[256],"Coronary Heart Disease",[235],{"trials":259,"activeCount":62},[260,269],{"nctId":261,"briefTitle":262,"status":129,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":268},"NCT03505021","Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS",[54],"2020-07-23","2018-06-21",496,[29],[216],{"nctId":270,"briefTitle":271,"status":103,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":277},"NCT03948178","Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension",[54],"2020-11-18","2019-06-26",227,[29],[216],{"trials":279,"activeCount":62},[280],{"nctId":281,"briefTitle":282,"status":129,"phases":283,"completion":284,"start":285,"enrollment":254,"conditions":286,"interventions":288},"NCT00219388","Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.",[55],"2005-04","2002-11",[287],"Heart Failure",[216],{"trials":290,"activeCount":62},[],{"intervention":138,"totalTrials":27,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":309,"PHASE3":311,"PHASE4":337,"NA":348},{"trials":294,"activeCount":62},[],{"trials":296,"activeCount":62},[297],{"nctId":298,"briefTitle":299,"status":129,"phases":300,"primaryCompletion":301,"completion":302,"start":303,"enrollment":304,"conditions":305,"interventions":308},"NCT00747721","Pharmacokinetics of Dexmedetomidine During Prolonged Infusion in ICU",[52],"2009-01","2009-02","2008-09",13,[306,307],"Pharmacokinetics","Sedation",[138],{"trials":310,"activeCount":62},[],{"trials":312,"activeCount":62},[313,317,327],{"nctId":127,"briefTitle":128,"status":129,"phases":314,"primaryCompletion":131,"completion":132,"start":133,"enrollment":134,"conditions":315,"interventions":316},[54],[136],[138,94],{"nctId":318,"briefTitle":319,"status":129,"phases":320,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":324,"interventions":325},"NCT00479661","Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU)",[54],"2010-03","2007-05",500,[136],[138,326],"Propofol",{"nctId":328,"briefTitle":329,"status":103,"phases":330,"completion":331,"start":332,"enrollment":333,"conditions":334,"interventions":336},"NCT00226785","Dexmedetomidine for Continuous Sedation",[54],"2006-07","2005-10",900,[335],"Conscious Sedation",[138],{"trials":338,"activeCount":62},[339],{"nctId":340,"briefTitle":341,"status":129,"phases":342,"primaryCompletion":343,"completion":343,"start":344,"enrollment":254,"conditions":345,"interventions":347},"NCT03813277","Safety, Tolerability and Efficacy of DEXDOR in Pediatric Patients in ICU",[55],"2018-05-21","2017-03-21",[346],"ICU Sedation",[138],{"trials":349,"activeCount":62},[],{"intervention":351,"totalTrials":27,"cells":352},"Stalevo",{"EARLY_PHASE1":353,"PHASE1":355,"PHASE2":367,"PHASE3":391,"PHASE4":393,"NA":416},{"trials":354,"activeCount":62},[],{"trials":356,"activeCount":62},[357],{"nctId":358,"briefTitle":359,"status":129,"phases":360,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":364,"interventions":365},"NCT01070628","Levodopa Concentration Profile With Stalevo 75\u002F125 mg",[52],"2010-02","2009-12",20,[21],[351,366],"Sinemet",{"trials":368,"activeCount":62},[369,379],{"nctId":370,"briefTitle":371,"status":129,"phases":372,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":376,"interventions":377},"NCT02764125","Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)",[53],"2018-03-27","2016-04-08",84,[21],[351,378],"levodopa MR",{"nctId":380,"briefTitle":381,"status":129,"phases":382,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":387,"interventions":388},"NCT01766258","Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations",[53],"2012-08","2012-09","2011-05",117,[21],[389,390,351],"ODM-101 65mg Carbidopa","ODM-101 105mg Carbidopa",{"trials":392,"activeCount":62},[],{"trials":394,"activeCount":62},[395,406],{"nctId":396,"briefTitle":397,"status":129,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},"NCT00125567","Stalevo in Early Wearing-Off Patients",[55],"2009-03","2005-08",223,[403],"Idiopathic Parkinson's Disease",[351,405],"Levodopa\u002Fcarbidopa",{"nctId":407,"briefTitle":408,"status":129,"phases":409,"primaryCompletion":410,"completion":411,"start":412,"enrollment":413,"conditions":414,"interventions":415},"NCT00462007","Study to Evaluate Initiation of Stalevo in Early Wearing-off",[55],"2007-08","2007-12","2006-09",115,[21],[351],{"trials":417,"activeCount":62},[],{"intervention":405,"totalTrials":8,"cells":419},{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":455},{"trials":421,"activeCount":62},[],{"trials":423,"activeCount":62},[424,436],{"nctId":425,"briefTitle":426,"status":129,"phases":427,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":431,"interventions":432},"NCT01840423","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers",[52],"2014-12","2013-05",101,[18],[433,434,435],"ODM-104","Entacapone","levodopa\u002Fcarbidopa",{"nctId":437,"briefTitle":438,"status":129,"phases":439,"primaryCompletion":440,"completion":440,"start":384,"enrollment":441,"conditions":442,"interventions":443},"NCT01688089","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers",[52],"2014-09",67,[18],[444,434,405],"ODM103",{"trials":446,"activeCount":62},[],{"trials":448,"activeCount":62},[],{"trials":450,"activeCount":62},[451],{"nctId":396,"briefTitle":397,"status":129,"phases":452,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":453,"interventions":454},[55],[403],[351,405],{"trials":456,"activeCount":62},[],{"intervention":458,"totalTrials":123,"cells":459},"Comtess®",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":478},{"trials":461,"activeCount":62},[],{"trials":463,"activeCount":62},[],{"trials":465,"activeCount":62},[],{"trials":467,"activeCount":62},[],{"trials":469,"activeCount":62},[470],{"nctId":471,"briefTitle":472,"status":129,"phases":473,"completion":474,"start":475,"enrollment":230,"conditions":476,"interventions":477},"NCT00247247","Comtess® Versus Cabaseril® as Add-on to Levodopa in the Treatment of Parkinsonian Patients Suffering From Wearing- Off.",[55],"2005-06","2002-12",[21],[458],{"trials":479,"activeCount":62},[],{"intervention":481,"totalTrials":123,"cells":482},"Polyethylene glycol 4000",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":503},{"trials":484,"activeCount":62},[],{"trials":486,"activeCount":62},[],{"trials":488,"activeCount":62},[],{"trials":490,"activeCount":62},[],{"trials":492,"activeCount":62},[493],{"nctId":494,"briefTitle":495,"status":129,"phases":496,"primaryCompletion":497,"completion":497,"start":498,"enrollment":441,"conditions":499,"interventions":501},"NCT00603681","Comparison of PEG Solutions With and Without Electrolytes in the Treatment of Constipation",[55],"2008-07","2008-01",[500],"Constipation",[481,502],"Polyethylene glycol 4000 with electrolytes",{"trials":504,"activeCount":62},[],{"intervention":502,"totalTrials":123,"cells":506},{"EARLY_PHASE1":507,"PHASE1":509,"PHASE2":511,"PHASE3":513,"PHASE4":515,"NA":521},{"trials":508,"activeCount":62},[],{"trials":510,"activeCount":62},[],{"trials":512,"activeCount":62},[],{"trials":514,"activeCount":62},[],{"trials":516,"activeCount":62},[517],{"nctId":494,"briefTitle":495,"status":129,"phases":518,"primaryCompletion":497,"completion":497,"start":498,"enrollment":441,"conditions":519,"interventions":520},[55],[500],[481,502],{"trials":522,"activeCount":62},[],{"intervention":524,"totalTrials":123,"cells":525},"Buventol® Easyhaler® 200 µg\u002Finhalation dmDPI",{"EARLY_PHASE1":526,"PHASE1":528,"PHASE2":530,"PHASE3":532,"PHASE4":534,"NA":547},{"trials":527,"activeCount":62},[],{"trials":529,"activeCount":62},[],{"trials":531,"activeCount":62},[],{"trials":533,"activeCount":62},[],{"trials":535,"activeCount":62},[536],{"nctId":537,"briefTitle":538,"status":129,"phases":539,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":543,"interventions":544},"NCT05084222","Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing",[55],"2023-06-30","2021-11-11",180,[15],[524,545,546],"Bufomix® Easyhaler® 160\u002F4.5 µg\u002Finhalation dmDPI","Ventoline® Evohaler® 100 µg\u002Finhalation pMDI",{"trials":548,"activeCount":62},[],{"intervention":545,"totalTrials":123,"cells":550},{"EARLY_PHASE1":551,"PHASE1":553,"PHASE2":555,"PHASE3":557,"PHASE4":559,"NA":565},{"trials":552,"activeCount":62},[],{"trials":554,"activeCount":62},[],{"trials":556,"activeCount":62},[],{"trials":558,"activeCount":62},[],{"trials":560,"activeCount":62},[561],{"nctId":537,"briefTitle":538,"status":129,"phases":562,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":563,"interventions":564},[55],[15],[524,545,546],{"trials":566,"activeCount":62},[],{"intervention":546,"totalTrials":123,"cells":568},{"EARLY_PHASE1":569,"PHASE1":571,"PHASE2":573,"PHASE3":575,"PHASE4":577,"NA":583},{"trials":570,"activeCount":62},[],{"trials":572,"activeCount":62},[],{"trials":574,"activeCount":62},[],{"trials":576,"activeCount":62},[],{"trials":578,"activeCount":62},[579],{"nctId":537,"briefTitle":538,"status":129,"phases":580,"primaryCompletion":540,"completion":540,"start":541,"enrollment":542,"conditions":581,"interventions":582},[55],[15],[524,545,546],{"trials":584,"activeCount":62},[],{"intervention":586,"totalTrials":34,"cells":587},"Ibuprofen",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":594,"PHASE4":612,"NA":614},{"trials":589,"activeCount":62},[],{"trials":591,"activeCount":62},[],{"trials":593,"activeCount":62},[],{"trials":595,"activeCount":62},[596,606],{"nctId":597,"briefTitle":598,"status":129,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":605},"NCT01562717","Efficacy and Safety of Ibuprofen in Patients With Ankle Injuries",[54],"2012-10","2012-02",62,[604],"Pain",[586],{"nctId":607,"briefTitle":598,"status":129,"phases":608,"primaryCompletion":609,"completion":609,"start":601,"enrollment":602,"conditions":610,"interventions":611},"NCT01563289",[54],"2012-07",[604],[586],{"trials":613,"activeCount":62},[],{"trials":615,"activeCount":62},[],{"intervention":326,"totalTrials":123,"cells":617},{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":624,"PHASE4":630,"NA":632},{"trials":619,"activeCount":62},[],{"trials":621,"activeCount":62},[],{"trials":623,"activeCount":62},[],{"trials":625,"activeCount":62},[626],{"nctId":318,"briefTitle":319,"status":129,"phases":627,"primaryCompletion":321,"completion":321,"start":322,"enrollment":323,"conditions":628,"interventions":629},[54],[136],[138,326],{"trials":631,"activeCount":62},[],{"trials":633,"activeCount":62},[],{"intervention":635,"totalTrials":123,"cells":636},"Budesonide\u002FFormoterol Easyhaler 320\u002F9 ug\u002Finhalation 4 inh",{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":641,"PHASE3":643,"PHASE4":656,"NA":658},{"trials":638,"activeCount":62},[],{"trials":640,"activeCount":62},[],{"trials":642,"activeCount":62},[],{"trials":644,"activeCount":62},[645],{"nctId":646,"briefTitle":647,"status":129,"phases":648,"primaryCompletion":649,"completion":649,"start":428,"enrollment":650,"conditions":651,"interventions":652},"NCT02308098","To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product",[54],"2015-06",72,[15],[635,653,654,655],"Budesonide\u002FFormoterol Easyhaler 320\u002F9 ug\u002Finhalation 1 inh","Symbicort Turbuhaler 320\u002F9 ug\u002Finhalation 4 inh","Symbicort Turbuhaler 320\u002F9 ug\u002Finhalation 1inh",{"trials":657,"activeCount":62},[],{"trials":659,"activeCount":62},[],{"intervention":653,"totalTrials":123,"cells":661},{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":668,"PHASE4":674,"NA":676},{"trials":663,"activeCount":62},[],{"trials":665,"activeCount":62},[],{"trials":667,"activeCount":62},[],{"trials":669,"activeCount":62},[670],{"nctId":646,"briefTitle":647,"status":129,"phases":671,"primaryCompletion":649,"completion":649,"start":428,"enrollment":650,"conditions":672,"interventions":673},[54],[15],[635,653,654,655],{"trials":675,"activeCount":62},[],{"trials":677,"activeCount":62},[],{"intervention":654,"totalTrials":123,"cells":679},{"EARLY_PHASE1":680,"PHASE1":682,"PHASE2":684,"PHASE3":686,"PHASE4":692,"NA":694},{"trials":681,"activeCount":62},[],{"trials":683,"activeCount":62},[],{"trials":685,"activeCount":62},[],{"trials":687,"activeCount":62},[688],{"nctId":646,"briefTitle":647,"status":129,"phases":689,"primaryCompletion":649,"completion":649,"start":428,"enrollment":650,"conditions":690,"interventions":691},[54],[15],[635,653,654,655],{"trials":693,"activeCount":62},[],{"trials":695,"activeCount":62},[],{"intervention":655,"totalTrials":123,"cells":697},{"EARLY_PHASE1":698,"PHASE1":700,"PHASE2":702,"PHASE3":704,"PHASE4":710,"NA":712},{"trials":699,"activeCount":62},[],{"trials":701,"activeCount":62},[],{"trials":703,"activeCount":62},[],{"trials":705,"activeCount":62},[706],{"nctId":646,"briefTitle":647,"status":129,"phases":707,"primaryCompletion":649,"completion":649,"start":428,"enrollment":650,"conditions":708,"interventions":709},[54],[15],[635,653,654,655],{"trials":711,"activeCount":62},[],{"trials":713,"activeCount":62},[],{"intervention":715,"totalTrials":716,"cells":717},"ORM-12741",9,{"EARLY_PHASE1":718,"PHASE1":727,"PHASE2":774,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":719,"activeCount":62},[720],{"nctId":721,"briefTitle":722,"status":129,"phases":723,"primaryCompletion":240,"completion":240,"start":301,"enrollment":11,"conditions":724,"interventions":725},"NCT00831077","Early Phase I Microdosing Study of ORM-14540 and ORM-12741",[51],[18],[726,715],"ORM-14540",{"trials":728,"activeCount":62},[729,736,743,752,760,767],{"nctId":730,"briefTitle":731,"status":129,"phases":732,"primaryCompletion":132,"completion":132,"start":497,"enrollment":733,"conditions":734,"interventions":735},"NCT00693316","Safety and Tolerability Study With Single Ascending Doses of ORM-12741",[52],120,[18],[715],{"nctId":737,"briefTitle":738,"status":129,"phases":739,"primaryCompletion":740,"completion":740,"start":301,"enrollment":12,"conditions":741,"interventions":742},"NCT00818740","Pharmacokinetic Study of ORM-12741 in Healthy Volunteers",[52],"2009-06",[23],[715],{"nctId":744,"briefTitle":745,"status":129,"phases":746,"primaryCompletion":747,"completion":748,"start":361,"enrollment":749,"conditions":750,"interventions":751},"NCT01068028","Safety and Pharmacokinetic Study With Multiple Ascending Doses of ORM-12741",[52],"2010-06","2010-07",49,[18],[715],{"nctId":753,"briefTitle":754,"status":129,"phases":755,"primaryCompletion":740,"completion":241,"start":756,"enrollment":757,"conditions":758,"interventions":759},"NCT00792493","Safety and Tolerability Study With Multiple Ascending Doses of ORM-12741",[52],"2008-12",51,[18],[715],{"nctId":761,"briefTitle":762,"status":129,"phases":763,"primaryCompletion":302,"completion":399,"start":301,"enrollment":11,"conditions":764,"interventions":766},"NCT00817544","Excretion Balance and Metabolism After a Single Oral Dose of 14C-Labelled ORM-12741",[52],[765],"Healthy Male Volunteers",[715],{"nctId":768,"briefTitle":769,"status":129,"phases":770,"primaryCompletion":740,"completion":740,"start":301,"enrollment":771,"conditions":772,"interventions":773},"NCT00829907","A PET Study With ORM-12741",[52],26,[18],[715],{"trials":775,"activeCount":62},[776,786],{"nctId":777,"briefTitle":778,"status":129,"phases":779,"primaryCompletion":780,"completion":781,"start":782,"enrollment":783,"conditions":784,"interventions":785},"NCT02471196","Efficacy of ORM-12741 on Agitation\u002FAggression Symptoms in Alzheimer's Disease",[53],"2017-10-09","2017-12-04","2015-08-14",308,[33],[715,715],{"nctId":787,"briefTitle":788,"status":129,"phases":789,"primaryCompletion":384,"completion":600,"start":790,"enrollment":6,"conditions":791,"interventions":792},"NCT01324518","Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease",[53],"2011-04",[33],[715,715],{"trials":794,"activeCount":62},[],{"trials":796,"activeCount":62},[],{"trials":798,"activeCount":62},[],{"intervention":800,"totalTrials":34,"cells":801},"ODM-201",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":803,"activeCount":62},[],{"trials":805,"activeCount":62},[],{"trials":807,"activeCount":62},[808,817],{"nctId":809,"briefTitle":810,"status":129,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":814,"conditions":815,"interventions":816},"NCT01429064","Safety and Tolerability of ODM-201 in Castrate Resistant Prostate Cancer; Extension Study to Study 3104001",[53],"2015-11","2011-06",76,[26],[800],{"nctId":818,"briefTitle":819,"status":129,"phases":820,"primaryCompletion":821,"completion":821,"start":822,"enrollment":823,"conditions":824,"interventions":825},"NCT01317641","Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer",[52,53],"2013-07","2011-03",136,[26],[800],{"trials":827,"activeCount":62},[],{"trials":829,"activeCount":62},[],{"trials":831,"activeCount":62},[],{"intervention":833,"totalTrials":34,"cells":834},"Carbidopa",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":849,"PHASE3":860,"PHASE4":862,"NA":864},{"trials":836,"activeCount":62},[],{"trials":838,"activeCount":62},[839],{"nctId":840,"briefTitle":841,"status":129,"phases":842,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":846,"interventions":847},"NCT03055936","Dose-finding Pharmacokinetic Study in Healthy Males",[52],"2017-06-09","2017-02-21",56,[23],[848,833,433],"Levodopa",{"trials":850,"activeCount":62},[851],{"nctId":852,"briefTitle":853,"status":129,"phases":854,"primaryCompletion":855,"completion":855,"start":856,"enrollment":857,"conditions":858,"interventions":859},"NCT01296464","Comparing Different Levodopa\u002FCarbidopa\u002FEntacapone Treatment Regimens",[53],"2011-07","2011-02",27,[21],[833],{"trials":861,"activeCount":62},[],{"trials":863,"activeCount":62},[],{"trials":865,"activeCount":62},[],{"intervention":867,"totalTrials":123,"cells":868},"budesonide and formoterol 200\u002F6 microg",{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":870,"activeCount":62},[],{"trials":872,"activeCount":62},[],{"trials":874,"activeCount":62},[875],{"nctId":876,"briefTitle":877,"status":129,"phases":878,"primaryCompletion":361,"completion":361,"start":241,"enrollment":879,"conditions":880,"interventions":881},"NCT00964535","Bioequivalence Study of Budesonide\u002FFormoterol Easyhaler and Symbicort Turbohaler in Asthmatics",[52,53],87,[15],[867,867,867,867],{"trials":883,"activeCount":62},[],{"trials":885,"activeCount":62},[],{"trials":887,"activeCount":62},[],{"intervention":378,"totalTrials":123,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":894,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":891,"activeCount":62},[],{"trials":893,"activeCount":62},[],{"trials":895,"activeCount":62},[896],{"nctId":370,"briefTitle":371,"status":129,"phases":897,"primaryCompletion":373,"completion":373,"start":374,"enrollment":375,"conditions":898,"interventions":899},[53],[21],[351,378],{"trials":901,"activeCount":62},[],{"trials":903,"activeCount":62},[],{"trials":905,"activeCount":62},[],{"intervention":907,"totalTrials":123,"cells":908},"ORM-12471 30mg",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":925,"PHASE4":927,"NA":929},{"trials":910,"activeCount":62},[],{"trials":912,"activeCount":62},[],{"trials":914,"activeCount":62},[915],{"nctId":916,"briefTitle":917,"status":103,"phases":918,"primaryCompletion":919,"completion":919,"start":822,"enrollment":920,"conditions":921,"interventions":923},"NCT01315899","Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon",[53],"2011-12",15,[922],"Raynaud's Phenomenon",[907,924],"ORM-12471",{"trials":926,"activeCount":62},[],{"trials":928,"activeCount":62},[],{"trials":930,"activeCount":62},[],{"intervention":924,"totalTrials":123,"cells":932},{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":943,"PHASE4":945,"NA":947},{"trials":934,"activeCount":62},[],{"trials":936,"activeCount":62},[],{"trials":938,"activeCount":62},[939],{"nctId":916,"briefTitle":917,"status":103,"phases":940,"primaryCompletion":919,"completion":919,"start":822,"enrollment":920,"conditions":941,"interventions":942},[53],[922],[907,924],{"trials":944,"activeCount":62},[],{"trials":946,"activeCount":62},[],{"trials":948,"activeCount":62},[],{"intervention":950,"totalTrials":123,"cells":951},"ODM-209",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":953,"activeCount":62},[],{"trials":955,"activeCount":62},[],{"trials":957,"activeCount":62},[958],{"nctId":959,"briefTitle":960,"status":129,"phases":961,"primaryCompletion":962,"completion":962,"start":963,"enrollment":964,"conditions":965,"interventions":969},"NCT03878823","Safety and Pharmacokinetics of ODM-209",[52,53],"2024-01-09","2019-04-17",38,[121,966,967,968],"Advanced Breast Cancer","Castration-resistant Prostate Cancer","Metastatic Breast Cancer",[950],{"trials":971,"activeCount":62},[],{"trials":973,"activeCount":62},[],{"trials":975,"activeCount":62},[],{"intervention":977,"totalTrials":123,"cells":978},"ODM-207",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":980,"activeCount":62},[],{"trials":982,"activeCount":62},[],{"trials":984,"activeCount":62},[985],{"nctId":986,"briefTitle":987,"status":129,"phases":988,"primaryCompletion":989,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT03035591","ODM-207 in Patients With Advance Solid Tumours",[52,53],"2019-05-10","2016-12-22",36,[993],"Solid Tumors",[977],{"trials":996,"activeCount":62},[],{"trials":998,"activeCount":62},[],{"trials":1000,"activeCount":62},[],{"intervention":1002,"totalTrials":123,"cells":1003},"ODM-204",{"EARLY_PHASE1":1004,"PHASE1":1006,"PHASE2":1008,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1005,"activeCount":62},[],{"trials":1007,"activeCount":62},[],{"trials":1009,"activeCount":62},[1010],{"nctId":1011,"briefTitle":1012,"status":129,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT02344017","Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer",[52,53],"2019-01","2015-02",23,[26],[1002,1019],"Prednisone",{"trials":1021,"activeCount":62},[],{"trials":1023,"activeCount":62},[],{"trials":1025,"activeCount":62},[],{"intervention":1019,"totalTrials":123,"cells":1027},{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1038,"PHASE4":1040,"NA":1042},{"trials":1029,"activeCount":62},[],{"trials":1031,"activeCount":62},[],{"trials":1033,"activeCount":62},[1034],{"nctId":1011,"briefTitle":1012,"status":129,"phases":1035,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":1016,"conditions":1036,"interventions":1037},[52,53],[26],[1002,1019],{"trials":1039,"activeCount":62},[],{"trials":1041,"activeCount":62},[],{"trials":1043,"activeCount":62},[],{"intervention":1045,"totalTrials":123,"cells":1046},"entacapone and carbidopa",{"EARLY_PHASE1":1047,"PHASE1":1049,"PHASE2":1051,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1048,"activeCount":62},[],{"trials":1050,"activeCount":62},[],{"trials":1052,"activeCount":62},[1053],{"nctId":1054,"briefTitle":1055,"status":103,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":498,"enrollment":1059,"conditions":1060,"interventions":1062},"NCT00562198","PET-Study: Effects of Single Doses of Stalevo and Levodopa\u002FCarbidopa on Striatal 11C-Raclopride Binding",[53],"2008-02","2008-05",16,[1061],"Parkinson´s Disease",[1045,1063],"Sinemet 200mg\u002F50mg",{"trials":1065,"activeCount":62},[],{"trials":1067,"activeCount":62},[],{"trials":1069,"activeCount":62},[],{"intervention":1063,"totalTrials":123,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1073,"activeCount":62},[],{"trials":1075,"activeCount":62},[],{"trials":1077,"activeCount":62},[1078],{"nctId":1054,"briefTitle":1055,"status":103,"phases":1079,"primaryCompletion":1057,"completion":1058,"start":498,"enrollment":1059,"conditions":1080,"interventions":1081},[53],[1061],[1045,1063],{"trials":1083,"activeCount":62},[],{"trials":1085,"activeCount":62},[],{"trials":1087,"activeCount":62},[],{"intervention":1089,"totalTrials":123,"cells":1090},"Tasipimidine",{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1095,"PHASE3":1109,"PHASE4":1111,"NA":1113},{"trials":1092,"activeCount":62},[],{"trials":1094,"activeCount":62},[],{"trials":1096,"activeCount":62},[1097],{"nctId":1098,"briefTitle":1099,"status":129,"phases":1100,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT06956495","Efficacy and Tolerability of Tasipimidine in Sleepless Patients",[53],"2025-09-11","2025-09-24","2023-08-20",190,[1106],"Insomnia",[1089,1108],"Tasipimidine placebo",{"trials":1110,"activeCount":62},[],{"trials":1112,"activeCount":62},[],{"trials":1114,"activeCount":62},[],{"intervention":1108,"totalTrials":123,"cells":1116},{"EARLY_PHASE1":1117,"PHASE1":1119,"PHASE2":1121,"PHASE3":1127,"PHASE4":1129,"NA":1131},{"trials":1118,"activeCount":62},[],{"trials":1120,"activeCount":62},[],{"trials":1122,"activeCount":62},[1123],{"nctId":1098,"briefTitle":1099,"status":129,"phases":1124,"primaryCompletion":1101,"completion":1102,"start":1103,"enrollment":1104,"conditions":1125,"interventions":1126},[53],[1106],[1089,1108],{"trials":1128,"activeCount":62},[],{"trials":1130,"activeCount":62},[],{"trials":1132,"activeCount":62},[],{"intervention":389,"totalTrials":123,"cells":1134},{"EARLY_PHASE1":1135,"PHASE1":1137,"PHASE2":1139,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1136,"activeCount":62},[],{"trials":1138,"activeCount":62},[],{"trials":1140,"activeCount":62},[1141],{"nctId":380,"briefTitle":381,"status":129,"phases":1142,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":1143,"interventions":1144},[53],[21],[389,390,351],{"trials":1146,"activeCount":62},[],{"trials":1148,"activeCount":62},[],{"trials":1150,"activeCount":62},[],{"intervention":390,"totalTrials":123,"cells":1152},{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1163,"PHASE4":1165,"NA":1167},{"trials":1154,"activeCount":62},[],{"trials":1156,"activeCount":62},[],{"trials":1158,"activeCount":62},[1159],{"nctId":380,"briefTitle":381,"status":129,"phases":1160,"primaryCompletion":383,"completion":384,"start":385,"enrollment":386,"conditions":1161,"interventions":1162},[53],[21],[389,390,351],{"trials":1164,"activeCount":62},[],{"trials":1166,"activeCount":62},[],{"trials":1168,"activeCount":62},[],{"intervention":1170,"totalTrials":123,"cells":1171},"ODM-109",{"EARLY_PHASE1":1172,"PHASE1":1174,"PHASE2":1176,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1173,"activeCount":62},[],{"trials":1175,"activeCount":62},[],{"trials":1177,"activeCount":62},[1178],{"nctId":1179,"briefTitle":1180,"status":129,"phases":1181,"primaryCompletion":1182,"completion":1183,"start":1184,"enrollment":1185,"conditions":1186,"interventions":1187},"NCT02487407","Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis",[53],"2017-05","2017-06","2015-07",66,[29],[1170],{"trials":1189,"activeCount":62},[],{"trials":1191,"activeCount":62},[],{"trials":1193,"activeCount":62},[],{"intervention":1195,"totalTrials":1196,"cells":1197},"Seretide Diskus",4,{"EARLY_PHASE1":1198,"PHASE1":1200,"PHASE2":1242,"PHASE3":1244,"PHASE4":1246,"NA":1248},{"trials":1199,"activeCount":62},[],{"trials":1201,"activeCount":62},[1202,1213,1225,1233],{"nctId":1203,"briefTitle":1204,"status":129,"phases":1205,"primaryCompletion":429,"completion":429,"start":1206,"enrollment":1207,"conditions":1208,"interventions":1209},"NCT01766843","Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol\u002FFluticasone Easyhaler and Seretide Diskus",[52],"2013-01",50,[15],[1210,1195,1211,1212],"Seretide Diskus and charcoal","SF Easyhaler and charcoal","SF Easyhaler",{"nctId":1214,"briefTitle":1215,"status":129,"phases":1216,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1220,"interventions":1221},"NCT03060044","Pharmacokinetic Study Comparing Salmeterol\u002FFluticasone Easyhaler and Seretide Diskus",[52],"2016-11","2016-07",64,[15],[1222,1223,1195,1224],"Salmeterol\u002Ffluticasone Easyhaler","Salmeterol\u002Ffluticasone Easyhaler with charcoal","Seretide Diskus with charcoal",{"nctId":1226,"briefTitle":1227,"status":129,"phases":1228,"primaryCompletion":1229,"completion":1229,"start":429,"enrollment":1230,"conditions":1231,"interventions":1232},"NCT01856621","Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol\u002FFluticasone Easyhaler With Seretide Diskus",[52],"2013-09",48,[15],[1210,1195,1211,1212],{"nctId":1234,"briefTitle":1235,"status":129,"phases":1236,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1239,"conditions":1240,"interventions":1241},"NCT02162485","Pharmacokinetic Study Comparing Salmeterol\u002FFluticasone Easyhaler Products and Seretide Diskus",[52],"2015-09","2014-06",129,[15],[1222,1223,1195,1224],{"trials":1243,"activeCount":62},[],{"trials":1245,"activeCount":62},[],{"trials":1247,"activeCount":62},[],{"trials":1249,"activeCount":62},[],{"intervention":1251,"totalTrials":8,"cells":1252},"levodopa, carbidopa, ODM-104",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1283,"PHASE3":1285,"PHASE4":1287,"NA":1289},{"trials":1254,"activeCount":62},[],{"trials":1256,"activeCount":62},[1257,1265,1276],{"nctId":1258,"briefTitle":1259,"status":129,"phases":1260,"primaryCompletion":812,"completion":812,"start":1261,"enrollment":920,"conditions":1262,"interventions":1263},"NCT02554734","Pharmacokinetic Study in Healthy Volunteers",[52],"2015-08",[21],[1251,1264],"levodopa, carbidopa, entacapone",{"nctId":1266,"briefTitle":1267,"status":129,"phases":1268,"primaryCompletion":1269,"completion":1270,"start":1271,"enrollment":363,"conditions":1272,"interventions":1274},"NCT03140956","Pharmacokinetic of Levodopa Study in Healthy Males",[52],"2017-07-03","2017-08-03","2017-04-19",[1273],"Parkinson Disease",[1275],"Levodopa, carbidopa, ODM-104",{"nctId":1277,"briefTitle":1278,"status":129,"phases":1279,"primaryCompletion":1015,"completion":1015,"start":1280,"enrollment":363,"conditions":1281,"interventions":1282},"NCT02312232","Pharmacokinetic Study in Healthy Males",[52],"2014-11",[21],[1251],{"trials":1284,"activeCount":62},[],{"trials":1286,"activeCount":62},[],{"trials":1288,"activeCount":62},[],{"trials":1290,"activeCount":62},[],{"intervention":1292,"totalTrials":8,"cells":1293},"Tiotropium Bromide Monohydrate",{"EARLY_PHASE1":1294,"PHASE1":1296,"PHASE2":1327,"PHASE3":1329,"PHASE4":1331,"NA":1333},{"trials":1295,"activeCount":62},[],{"trials":1297,"activeCount":62},[1298,1308,1318],{"nctId":1299,"briefTitle":1300,"status":129,"phases":1301,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1304,"conditions":1305,"interventions":1306},"NCT04850144","Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler®",[52],"2021-10-04","2021-04-26",43,[23],[1292,1292,1292,1292,1292,1292,1307],"Tiotropium Easyhaler with oral activated charcoal",{"nctId":1309,"briefTitle":1310,"status":129,"phases":1311,"primaryCompletion":1312,"completion":1312,"start":1313,"enrollment":1314,"conditions":1315,"interventions":1317},"NCT03400241","Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler",[52],"2018-04-18","2018-02-19",24,[1316],"Healthy Subjects",[1292,1292,1292,1292],{"nctId":1319,"briefTitle":1320,"status":129,"phases":1321,"primaryCompletion":1322,"completion":1322,"start":1323,"enrollment":1324,"conditions":1325,"interventions":1326},"NCT05246046","Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler",[52],"2022-08-03","2022-02-16",88,[23],[1292],{"trials":1328,"activeCount":62},[],{"trials":1330,"activeCount":62},[],{"trials":1332,"activeCount":62},[],{"trials":1334,"activeCount":62},[],{"intervention":433,"totalTrials":8,"cells":1336},{"EARLY_PHASE1":1337,"PHASE1":1339,"PHASE2":1359,"PHASE3":1361,"PHASE4":1363,"NA":1365},{"trials":1338,"activeCount":62},[],{"trials":1340,"activeCount":62},[1341,1345,1355],{"nctId":425,"briefTitle":426,"status":129,"phases":1342,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":1343,"interventions":1344},[52],[18],[433,434,435],{"nctId":1346,"briefTitle":1347,"status":129,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1196,"conditions":1351,"interventions":1353},"NCT04571996","Blood-Brain Barrier Penetration of Therapeutic Agents in Human",[52],"2021-02-23","2020-10-29",[1352],"CNS Disease",[433,1354],"Paracetamol",{"nctId":840,"briefTitle":841,"status":129,"phases":1356,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":1357,"interventions":1358},[52],[23],[848,833,433],{"trials":1360,"activeCount":62},[],{"trials":1362,"activeCount":62},[],{"trials":1364,"activeCount":62},[],{"trials":1366,"activeCount":62},[],{"intervention":1264,"totalTrials":34,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1387,"PHASE3":1389,"PHASE4":1391,"NA":1393},{"trials":1370,"activeCount":62},[],{"trials":1372,"activeCount":62},[1373,1377],{"nctId":1258,"briefTitle":1259,"status":129,"phases":1374,"primaryCompletion":812,"completion":812,"start":1261,"enrollment":920,"conditions":1375,"interventions":1376},[52],[21],[1251,1264],{"nctId":1378,"briefTitle":1379,"status":129,"phases":1380,"primaryCompletion":1381,"completion":1058,"start":1382,"enrollment":1383,"conditions":1384,"interventions":1385},"NCT00693862","Pharmacokinetic Study With Repeated Doses of Stalevo",[52],"2008-04","2006-12",19,[306],[1264,1386],"levodopa, carbidopa",{"trials":1388,"activeCount":62},[],{"trials":1390,"activeCount":62},[],{"trials":1392,"activeCount":62},[],{"trials":1394,"activeCount":62},[],{"intervention":1396,"totalTrials":34,"cells":1397},"Alprazolam",{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1417,"PHASE3":1419,"PHASE4":1421,"NA":1423},{"trials":1399,"activeCount":62},[],{"trials":1401,"activeCount":62},[1402,1408],{"nctId":1403,"briefTitle":1404,"status":129,"phases":1405,"primaryCompletion":740,"completion":740,"start":240,"enrollment":19,"conditions":1406,"interventions":1407},"NCT00878865","Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets",[52],[18],[1396,1396],{"nctId":1409,"briefTitle":1410,"status":129,"phases":1411,"primaryCompletion":740,"completion":1412,"start":1413,"enrollment":19,"conditions":1414,"interventions":1415},"NCT00878514","Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions",[52],"2009-07","2009-05",[18],[1396,1416],"Xanax",{"trials":1418,"activeCount":62},[],{"trials":1420,"activeCount":62},[],{"trials":1422,"activeCount":62},[],{"trials":1424,"activeCount":62},[],{"intervention":1426,"totalTrials":34,"cells":1427},"Budesonide\u002Fformoterol Easyhaler",{"EARLY_PHASE1":1428,"PHASE1":1430,"PHASE2":1450,"PHASE3":1452,"PHASE4":1454,"NA":1456},{"trials":1429,"activeCount":62},[],{"trials":1431,"activeCount":62},[1432,1442],{"nctId":1433,"briefTitle":1434,"status":129,"phases":1435,"primaryCompletion":600,"completion":600,"start":1436,"enrollment":650,"conditions":1437,"interventions":1438},"NCT01627158","Pharmacokinetic Study Comparing Budesonide\u002FFormoterol Easyhaler and Symbicort Turbuhaler Forte",[52],"2012-06",[15],[1426,1439,1440,1441],"Symbicort Turbuhaler","Charcoal and Budesonide\u002Fformoterol Easyhaler","Charcoal and Symbicort Turbuhaler",{"nctId":1443,"briefTitle":1444,"status":129,"phases":1445,"primaryCompletion":1446,"completion":1446,"start":383,"enrollment":1230,"conditions":1447,"interventions":1448},"NCT01668121","Pharmacokinetic Study on Budesonide\u002FFormoterol Device-metered Dry Powder Inhalers",[52],"2012-11",[15],[1449,1426],"Symbicort Turbohaler",{"trials":1451,"activeCount":62},[],{"trials":1453,"activeCount":62},[],{"trials":1455,"activeCount":62},[],{"trials":1457,"activeCount":62},[],{"intervention":1439,"totalTrials":34,"cells":1459},{"EARLY_PHASE1":1460,"PHASE1":1462,"PHASE2":1477,"PHASE3":1479,"PHASE4":1481,"NA":1483},{"trials":1461,"activeCount":62},[],{"trials":1463,"activeCount":62},[1464,1468],{"nctId":1433,"briefTitle":1434,"status":129,"phases":1465,"primaryCompletion":600,"completion":600,"start":1436,"enrollment":650,"conditions":1466,"interventions":1467},[52],[15],[1426,1439,1440,1441],{"nctId":1469,"briefTitle":1470,"status":129,"phases":1471,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":363,"conditions":1474,"interventions":1475},"NCT03073057","Pharmacokinetic Study to Compare Absorption of Budesonide\u002FFormoterol Easyhaler and Symbicort Turbuhaler",[52],"2016-03","2016-01",[15],[1476,1439],"Budesonide\u002Fformoterol",{"trials":1478,"activeCount":62},[],{"trials":1480,"activeCount":62},[],{"trials":1482,"activeCount":62},[],{"trials":1484,"activeCount":62},[],{"intervention":1441,"totalTrials":34,"cells":1486},{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1505,"PHASE3":1507,"PHASE4":1509,"NA":1511},{"trials":1488,"activeCount":62},[],{"trials":1490,"activeCount":62},[1491,1495],{"nctId":1433,"briefTitle":1434,"status":129,"phases":1492,"primaryCompletion":600,"completion":600,"start":1436,"enrollment":650,"conditions":1493,"interventions":1494},[52],[15],[1426,1439,1440,1441],{"nctId":1496,"briefTitle":1497,"status":129,"phases":1498,"primaryCompletion":600,"completion":600,"start":1499,"enrollment":650,"conditions":1500,"interventions":1501},"NCT01593826","Comparison of Absorption of Budesonide and Formoterol From Budesonide\u002FFormoterol Easyhaler and Symbicort Turbuhaler",[52],"2012-05",[15],[1502,1441,1503,1504],"Charcoal and Budesonide\u002Fformoterol Easyhaler 320\u002F9 microg","Budesonide\u002Fformoterol Easyhaler 320\u002F9 microg","Symbicort Turbuhaler forte",{"trials":1506,"activeCount":62},[],{"trials":1508,"activeCount":62},[],{"trials":1510,"activeCount":62},[],{"trials":1512,"activeCount":62},[],{"intervention":1210,"totalTrials":34,"cells":1514},{"EARLY_PHASE1":1515,"PHASE1":1517,"PHASE2":1527,"PHASE3":1529,"PHASE4":1531,"NA":1533},{"trials":1516,"activeCount":62},[],{"trials":1518,"activeCount":62},[1519,1523],{"nctId":1203,"briefTitle":1204,"status":129,"phases":1520,"primaryCompletion":429,"completion":429,"start":1206,"enrollment":1207,"conditions":1521,"interventions":1522},[52],[15],[1210,1195,1211,1212],{"nctId":1226,"briefTitle":1227,"status":129,"phases":1524,"primaryCompletion":1229,"completion":1229,"start":429,"enrollment":1230,"conditions":1525,"interventions":1526},[52],[15],[1210,1195,1211,1212],{"trials":1528,"activeCount":62},[],{"trials":1530,"activeCount":62},[],{"trials":1532,"activeCount":62},[],{"trials":1534,"activeCount":62},[],{"intervention":1211,"totalTrials":34,"cells":1536},{"EARLY_PHASE1":1537,"PHASE1":1539,"PHASE2":1549,"PHASE3":1551,"PHASE4":1553,"NA":1555},{"trials":1538,"activeCount":62},[],{"trials":1540,"activeCount":62},[1541,1545],{"nctId":1203,"briefTitle":1204,"status":129,"phases":1542,"primaryCompletion":429,"completion":429,"start":1206,"enrollment":1207,"conditions":1543,"interventions":1544},[52],[15],[1210,1195,1211,1212],{"nctId":1226,"briefTitle":1227,"status":129,"phases":1546,"primaryCompletion":1229,"completion":1229,"start":429,"enrollment":1230,"conditions":1547,"interventions":1548},[52],[15],[1210,1195,1211,1212],{"trials":1550,"activeCount":62},[],{"trials":1552,"activeCount":62},[],{"trials":1554,"activeCount":62},[],{"trials":1556,"activeCount":62},[],{"intervention":1212,"totalTrials":34,"cells":1558},{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1571,"PHASE3":1573,"PHASE4":1575,"NA":1577},{"trials":1560,"activeCount":62},[],{"trials":1562,"activeCount":62},[1563,1567],{"nctId":1203,"briefTitle":1204,"status":129,"phases":1564,"primaryCompletion":429,"completion":429,"start":1206,"enrollment":1207,"conditions":1565,"interventions":1566},[52],[15],[1210,1195,1211,1212],{"nctId":1226,"briefTitle":1227,"status":129,"phases":1568,"primaryCompletion":1229,"completion":1229,"start":429,"enrollment":1230,"conditions":1569,"interventions":1570},[52],[15],[1210,1195,1211,1212],{"trials":1572,"activeCount":62},[],{"trials":1574,"activeCount":62},[],{"trials":1576,"activeCount":62},[],{"trials":1578,"activeCount":62},[],{"intervention":1580,"totalTrials":34,"cells":1581},"ORM-12741 MR A",{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1583,"activeCount":62},[],{"trials":1585,"activeCount":62},[1586,1596],{"nctId":1587,"briefTitle":1588,"status":129,"phases":1589,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":920,"conditions":1592,"interventions":1593},"NCT02303860","Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)",[52],"2015-01","2014-10",[18],[1580,1594,1595],"ORM-12741 MR B","ORM-12741 IR",{"nctId":1597,"briefTitle":1598,"status":129,"phases":1599,"primaryCompletion":1015,"completion":1015,"start":440,"enrollment":1016,"conditions":1600,"interventions":1601},"NCT02319057","Pharmacokinetic Study of Single Doses of ORM-12741",[52],[18],[1580,1595,1594],{"trials":1603,"activeCount":62},[],{"trials":1605,"activeCount":62},[],{"trials":1607,"activeCount":62},[],{"trials":1609,"activeCount":62},[],{"intervention":1594,"totalTrials":34,"cells":1611},{"EARLY_PHASE1":1612,"PHASE1":1614,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1630},{"trials":1613,"activeCount":62},[],{"trials":1615,"activeCount":62},[1616,1620],{"nctId":1587,"briefTitle":1588,"status":129,"phases":1617,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":920,"conditions":1618,"interventions":1619},[52],[18],[1580,1594,1595],{"nctId":1597,"briefTitle":1598,"status":129,"phases":1621,"primaryCompletion":1015,"completion":1015,"start":440,"enrollment":1016,"conditions":1622,"interventions":1623},[52],[18],[1580,1595,1594],{"trials":1625,"activeCount":62},[],{"trials":1627,"activeCount":62},[],{"trials":1629,"activeCount":62},[],{"trials":1631,"activeCount":62},[],{"intervention":1595,"totalTrials":34,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1646,"PHASE3":1648,"PHASE4":1650,"NA":1652},{"trials":1635,"activeCount":62},[],{"trials":1637,"activeCount":62},[1638,1642],{"nctId":1587,"briefTitle":1588,"status":129,"phases":1639,"primaryCompletion":1590,"completion":1590,"start":1591,"enrollment":920,"conditions":1640,"interventions":1641},[52],[18],[1580,1594,1595],{"nctId":1597,"briefTitle":1598,"status":129,"phases":1643,"primaryCompletion":1015,"completion":1015,"start":440,"enrollment":1016,"conditions":1644,"interventions":1645},[52],[18],[1580,1595,1594],{"trials":1647,"activeCount":62},[],{"trials":1649,"activeCount":62},[],{"trials":1651,"activeCount":62},[],{"trials":1653,"activeCount":62},[],{"intervention":1222,"totalTrials":34,"cells":1655},{"EARLY_PHASE1":1656,"PHASE1":1658,"PHASE2":1668,"PHASE3":1670,"PHASE4":1672,"NA":1674},{"trials":1657,"activeCount":62},[],{"trials":1659,"activeCount":62},[1660,1664],{"nctId":1214,"briefTitle":1215,"status":129,"phases":1661,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1662,"interventions":1663},[52],[15],[1222,1223,1195,1224],{"nctId":1234,"briefTitle":1235,"status":129,"phases":1665,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1239,"conditions":1666,"interventions":1667},[52],[15],[1222,1223,1195,1224],{"trials":1669,"activeCount":62},[],{"trials":1671,"activeCount":62},[],{"trials":1673,"activeCount":62},[],{"trials":1675,"activeCount":62},[],{"intervention":1223,"totalTrials":34,"cells":1677},{"EARLY_PHASE1":1678,"PHASE1":1680,"PHASE2":1690,"PHASE3":1692,"PHASE4":1694,"NA":1696},{"trials":1679,"activeCount":62},[],{"trials":1681,"activeCount":62},[1682,1686],{"nctId":1214,"briefTitle":1215,"status":129,"phases":1683,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1684,"interventions":1685},[52],[15],[1222,1223,1195,1224],{"nctId":1234,"briefTitle":1235,"status":129,"phases":1687,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1239,"conditions":1688,"interventions":1689},[52],[15],[1222,1223,1195,1224],{"trials":1691,"activeCount":62},[],{"trials":1693,"activeCount":62},[],{"trials":1695,"activeCount":62},[],{"trials":1697,"activeCount":62},[],{"intervention":1224,"totalTrials":34,"cells":1699},{"EARLY_PHASE1":1700,"PHASE1":1702,"PHASE2":1712,"PHASE3":1714,"PHASE4":1716,"NA":1718},{"trials":1701,"activeCount":62},[],{"trials":1703,"activeCount":62},[1704,1708],{"nctId":1214,"briefTitle":1215,"status":129,"phases":1705,"primaryCompletion":1217,"completion":1217,"start":1218,"enrollment":1219,"conditions":1706,"interventions":1707},[52],[15],[1222,1223,1195,1224],{"nctId":1234,"briefTitle":1235,"status":129,"phases":1709,"primaryCompletion":1237,"completion":1237,"start":1238,"enrollment":1239,"conditions":1710,"interventions":1711},[52],[15],[1222,1223,1195,1224],{"trials":1713,"activeCount":62},[],{"trials":1715,"activeCount":62},[],{"trials":1717,"activeCount":62},[],{"trials":1719,"activeCount":62},[],{"intervention":1503,"totalTrials":34,"cells":1721},{"EARLY_PHASE1":1722,"PHASE1":1724,"PHASE2":1738,"PHASE3":1740,"PHASE4":1742,"NA":1744},{"trials":1723,"activeCount":62},[],{"trials":1725,"activeCount":62},[1726,1734],{"nctId":1727,"briefTitle":1728,"status":129,"phases":1729,"primaryCompletion":1730,"completion":1730,"start":855,"enrollment":1731,"conditions":1732,"interventions":1733},"NCT01386996","Comparison of Budesonide and Formoterol Absorption From Budesonide\u002FFormoterol Easyhaler and Symbicort Turbuhaler",[52],"2011-11",74,[15],[1503,1504],{"nctId":1496,"briefTitle":1497,"status":129,"phases":1735,"primaryCompletion":600,"completion":600,"start":1499,"enrollment":650,"conditions":1736,"interventions":1737},[52],[15],[1502,1441,1503,1504],{"trials":1739,"activeCount":62},[],{"trials":1741,"activeCount":62},[],{"trials":1743,"activeCount":62},[],{"trials":1745,"activeCount":62},[],{"intervention":1504,"totalTrials":34,"cells":1747},{"EARLY_PHASE1":1748,"PHASE1":1750,"PHASE2":1760,"PHASE3":1762,"PHASE4":1764,"NA":1766},{"trials":1749,"activeCount":62},[],{"trials":1751,"activeCount":62},[1752,1756],{"nctId":1727,"briefTitle":1728,"status":129,"phases":1753,"primaryCompletion":1730,"completion":1730,"start":855,"enrollment":1731,"conditions":1754,"interventions":1755},[52],[15],[1503,1504],{"nctId":1496,"briefTitle":1497,"status":129,"phases":1757,"primaryCompletion":600,"completion":600,"start":1499,"enrollment":650,"conditions":1758,"interventions":1759},[52],[15],[1502,1441,1503,1504],{"trials":1761,"activeCount":62},[],{"trials":1763,"activeCount":62},[],{"trials":1765,"activeCount":62},[],{"trials":1767,"activeCount":62},[],{"intervention":434,"totalTrials":34,"cells":1769},{"EARLY_PHASE1":1770,"PHASE1":1772,"PHASE2":1782,"PHASE3":1784,"PHASE4":1786,"NA":1788},{"trials":1771,"activeCount":62},[],{"trials":1773,"activeCount":62},[1774,1778],{"nctId":425,"briefTitle":426,"status":129,"phases":1775,"primaryCompletion":428,"completion":428,"start":429,"enrollment":430,"conditions":1776,"interventions":1777},[52],[18],[433,434,435],{"nctId":437,"briefTitle":438,"status":129,"phases":1779,"primaryCompletion":440,"completion":440,"start":384,"enrollment":441,"conditions":1780,"interventions":1781},[52],[18],[444,434,405],{"trials":1783,"activeCount":62},[],{"trials":1785,"activeCount":62},[],{"trials":1787,"activeCount":62},[],{"trials":1789,"activeCount":62},[],{"intervention":1791,"totalTrials":123,"cells":1792},"Budesonide\u002Fformoterol 320\u002F9 μg and 400\u002F12 μg inhalers",{"EARLY_PHASE1":1793,"PHASE1":1795,"PHASE2":1806,"PHASE3":1808,"PHASE4":1810,"NA":1812},{"trials":1794,"activeCount":62},[],{"trials":1796,"activeCount":62},[1797],{"nctId":1798,"briefTitle":1799,"status":129,"phases":1800,"primaryCompletion":1801,"completion":1802,"start":1803,"enrollment":363,"conditions":1804,"interventions":1805},"NCT01181063","Pharmacokinetic Pilot Study on Budesonide\u002FFormoterol Device-metered Dry Powder Inhalers",[52],"2010-10","2010-11","2010-08",[15],[1791],{"trials":1807,"activeCount":62},[],{"trials":1809,"activeCount":62},[],{"trials":1811,"activeCount":62},[],{"trials":1813,"activeCount":62},[],{"intervention":1815,"totalTrials":123,"cells":1816},"Indacaterol maleate and glycopyrronium bromide",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1831,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1818,"activeCount":62},[],{"trials":1820,"activeCount":62},[1821],{"nctId":1822,"briefTitle":1823,"status":129,"phases":1824,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":1827,"conditions":1828,"interventions":1829},"NCT04856098","Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler",[52],"2021-09-21","2021-05-07",34,[23],[1815,1815,1815,1830],"Ultibro Breezhaler with oral charcoal",{"trials":1832,"activeCount":62},[],{"trials":1834,"activeCount":62},[],{"trials":1836,"activeCount":62},[],{"trials":1838,"activeCount":62},[],{"intervention":1830,"totalTrials":123,"cells":1840},{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1849,"PHASE3":1851,"PHASE4":1853,"NA":1855},{"trials":1842,"activeCount":62},[],{"trials":1844,"activeCount":62},[1845],{"nctId":1822,"briefTitle":1823,"status":129,"phases":1846,"primaryCompletion":1825,"completion":1825,"start":1826,"enrollment":1827,"conditions":1847,"interventions":1848},[52],[23],[1815,1815,1815,1830],{"trials":1850,"activeCount":62},[],{"trials":1852,"activeCount":62},[],{"trials":1854,"activeCount":62},[],{"trials":1856,"activeCount":62},[],{"intervention":1858,"totalTrials":123,"cells":1859},"Budesonide\u002FFormoterol Batch 1",{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1872,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1861,"activeCount":62},[],{"trials":1863,"activeCount":62},[1864],{"nctId":1865,"briefTitle":1866,"status":129,"phases":1867,"primaryCompletion":1413,"completion":1413,"start":240,"enrollment":12,"conditions":1868,"interventions":1869},"NCT00868426","Pharmacokinetic Pilot Study on Budesonide\u002FFormoterol Device-metered Dry Powder Inhaler",[52],[18],[1858,1870,1871],"Budesonide\u002FFormoterol Batch 2","Budesonide\u002FFormoterol Batch 1 and charcoal",{"trials":1873,"activeCount":62},[],{"trials":1875,"activeCount":62},[],{"trials":1877,"activeCount":62},[],{"trials":1879,"activeCount":62},[],{"intervention":1870,"totalTrials":123,"cells":1881},{"EARLY_PHASE1":1882,"PHASE1":1884,"PHASE2":1890,"PHASE3":1892,"PHASE4":1894,"NA":1896},{"trials":1883,"activeCount":62},[],{"trials":1885,"activeCount":62},[1886],{"nctId":1865,"briefTitle":1866,"status":129,"phases":1887,"primaryCompletion":1413,"completion":1413,"start":240,"enrollment":12,"conditions":1888,"interventions":1889},[52],[18],[1858,1870,1871],{"trials":1891,"activeCount":62},[],{"trials":1893,"activeCount":62},[],{"trials":1895,"activeCount":62},[],{"trials":1897,"activeCount":62},[],{"intervention":1871,"totalTrials":123,"cells":1899},{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1908,"PHASE3":1910,"PHASE4":1912,"NA":1914},{"trials":1901,"activeCount":62},[],{"trials":1903,"activeCount":62},[1904],{"nctId":1865,"briefTitle":1866,"status":129,"phases":1905,"primaryCompletion":1413,"completion":1413,"start":240,"enrollment":12,"conditions":1906,"interventions":1907},[52],[18],[1858,1870,1871],{"trials":1909,"activeCount":62},[],{"trials":1911,"activeCount":62},[],{"trials":1913,"activeCount":62},[],{"trials":1915,"activeCount":62},[],{"intervention":1307,"totalTrials":123,"cells":1917},{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1926,"PHASE3":1928,"PHASE4":1930,"NA":1932},{"trials":1919,"activeCount":62},[],{"trials":1921,"activeCount":62},[1922],{"nctId":1299,"briefTitle":1300,"status":129,"phases":1923,"primaryCompletion":1302,"completion":1302,"start":1303,"enrollment":1304,"conditions":1924,"interventions":1925},[52],[23],[1292,1292,1292,1292,1292,1292,1307],{"trials":1927,"activeCount":62},[],{"trials":1929,"activeCount":62},[],{"trials":1931,"activeCount":62},[],{"trials":1933,"activeCount":62},[],{"intervention":1935,"totalTrials":123,"cells":1936},"ODM-201 300 mg",{"EARLY_PHASE1":1937,"PHASE1":1939,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1957},{"trials":1938,"activeCount":62},[],{"trials":1940,"activeCount":62},[1941],{"nctId":1942,"briefTitle":1943,"status":129,"phases":1944,"primaryCompletion":1945,"completion":649,"start":1946,"enrollment":12,"conditions":1947,"interventions":1948},"NCT02418650","Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects",[52],"2015-05","2015-03",[18],[1935,1949,1950],"intravenous14C-ODM-201","300 mg 14C-ODM-201 oral solution",{"trials":1952,"activeCount":62},[],{"trials":1954,"activeCount":62},[],{"trials":1956,"activeCount":62},[],{"trials":1958,"activeCount":62},[],{"intervention":1949,"totalTrials":123,"cells":1960},{"EARLY_PHASE1":1961,"PHASE1":1963,"PHASE2":1969,"PHASE3":1971,"PHASE4":1973,"NA":1975},{"trials":1962,"activeCount":62},[],{"trials":1964,"activeCount":62},[1965],{"nctId":1942,"briefTitle":1943,"status":129,"phases":1966,"primaryCompletion":1945,"completion":649,"start":1946,"enrollment":12,"conditions":1967,"interventions":1968},[52],[18],[1935,1949,1950],{"trials":1970,"activeCount":62},[],{"trials":1972,"activeCount":62},[],{"trials":1974,"activeCount":62},[],{"trials":1976,"activeCount":62},[],{"intervention":1950,"totalTrials":123,"cells":1978},{"EARLY_PHASE1":1979,"PHASE1":1981,"PHASE2":1987,"PHASE3":1989,"PHASE4":1991,"NA":1993},{"trials":1980,"activeCount":62},[],{"trials":1982,"activeCount":62},[1983],{"nctId":1942,"briefTitle":1943,"status":129,"phases":1984,"primaryCompletion":1945,"completion":649,"start":1946,"enrollment":12,"conditions":1985,"interventions":1986},[52],[18],[1935,1949,1950],{"trials":1988,"activeCount":62},[],{"trials":1990,"activeCount":62},[],{"trials":1992,"activeCount":62},[],{"trials":1994,"activeCount":62},[],{"intervention":1440,"totalTrials":123,"cells":1996},{"EARLY_PHASE1":1997,"PHASE1":1999,"PHASE2":2005,"PHASE3":2007,"PHASE4":2009,"NA":2011},{"trials":1998,"activeCount":62},[],{"trials":2000,"activeCount":62},[2001],{"nctId":1433,"briefTitle":1434,"status":129,"phases":2002,"primaryCompletion":600,"completion":600,"start":1436,"enrollment":650,"conditions":2003,"interventions":2004},[52],[15],[1426,1439,1440,1441],{"trials":2006,"activeCount":62},[],{"trials":2008,"activeCount":62},[],{"trials":2010,"activeCount":62},[],{"trials":2012,"activeCount":62},[],{"intervention":2014,"totalTrials":123,"cells":2015},"salmeterol-fluticasone",{"EARLY_PHASE1":2016,"PHASE1":2018,"PHASE2":2028,"PHASE3":2030,"PHASE4":2032,"NA":2034},{"trials":2017,"activeCount":62},[],{"trials":2019,"activeCount":62},[2020],{"nctId":2021,"briefTitle":2022,"status":129,"phases":2023,"primaryCompletion":2024,"completion":2024,"start":2025,"enrollment":1219,"conditions":2026,"interventions":2027},"NCT03238482","Comparing Salmeterol\u002FFluticasone Easyhaler and Seretide Diskus (SAIMI)",[52],"2017-12-19","2017-08-16",[15],[2014,2014,2014,2014],{"trials":2029,"activeCount":62},[],{"trials":2031,"activeCount":62},[],{"trials":2033,"activeCount":62},[],{"trials":2035,"activeCount":62},[],{"intervention":2037,"totalTrials":123,"cells":2038},"Spironolactone",{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2057},{"trials":2040,"activeCount":62},[],{"trials":2042,"activeCount":62},[2043],{"nctId":2044,"briefTitle":2045,"status":129,"phases":2046,"primaryCompletion":2047,"completion":2047,"start":2047,"enrollment":2048,"conditions":2049,"interventions":2050},"NCT01083290","Pharmacokinetic Study of Spironolactone 25 mg, 50 mg and 100 mg Tablets",[52],"2010-04",14,[18],[2037,2037,2037],{"trials":2052,"activeCount":62},[],{"trials":2054,"activeCount":62},[],{"trials":2056,"activeCount":62},[],{"trials":2058,"activeCount":62},[],{"intervention":2060,"totalTrials":123,"cells":2061},"11C-ORM-13070",{"EARLY_PHASE1":2062,"PHASE1":2064,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2078},{"trials":2063,"activeCount":62},[],{"trials":2065,"activeCount":62},[2066],{"nctId":2067,"briefTitle":2068,"status":129,"phases":2069,"primaryCompletion":1413,"completion":1413,"start":242,"enrollment":19,"conditions":2070,"interventions":2071},"NCT00735774","Suitability of 11C-ORM-13070 as a PET Tracer",[52],[18],[2060],{"trials":2073,"activeCount":62},[],{"trials":2075,"activeCount":62},[],{"trials":2077,"activeCount":62},[],{"trials":2079,"activeCount":62},[],{"intervention":2081,"totalTrials":123,"cells":2082},"ODM-203",{"EARLY_PHASE1":2083,"PHASE1":2085,"PHASE2":2095,"PHASE3":2097,"PHASE4":2099,"NA":2101},{"trials":2084,"activeCount":62},[],{"trials":2086,"activeCount":62},[2087],{"nctId":2088,"briefTitle":2089,"status":129,"phases":2090,"primaryCompletion":2091,"completion":2091,"start":2092,"enrollment":1059,"conditions":2093,"interventions":2094},"NCT03240445","Impact of Changing the Dosing Regimen on the PK Profile of ODM-203",[52],"2017-10-23","2017-08-24",[18],[2081,2081,2081],{"trials":2096,"activeCount":62},[],{"trials":2098,"activeCount":62},[],{"trials":2100,"activeCount":62},[],{"trials":2102,"activeCount":62},[],{"intervention":444,"totalTrials":123,"cells":2104},{"EARLY_PHASE1":2105,"PHASE1":2107,"PHASE2":2113,"PHASE3":2115,"PHASE4":2117,"NA":2119},{"trials":2106,"activeCount":62},[],{"trials":2108,"activeCount":62},[2109],{"nctId":437,"briefTitle":438,"status":129,"phases":2110,"primaryCompletion":440,"completion":440,"start":384,"enrollment":441,"conditions":2111,"interventions":2112},[52],[18],[444,434,405],{"trials":2114,"activeCount":62},[],{"trials":2116,"activeCount":62},[],{"trials":2118,"activeCount":62},[],{"trials":2120,"activeCount":62},[],{"intervention":1386,"totalTrials":123,"cells":2122},{"EARLY_PHASE1":2123,"PHASE1":2125,"PHASE2":2131,"PHASE3":2133,"PHASE4":2135,"NA":2137},{"trials":2124,"activeCount":62},[],{"trials":2126,"activeCount":62},[2127],{"nctId":1378,"briefTitle":1379,"status":129,"phases":2128,"primaryCompletion":1381,"completion":1058,"start":1382,"enrollment":1383,"conditions":2129,"interventions":2130},[52],[306],[1264,1386],{"trials":2132,"activeCount":62},[],{"trials":2134,"activeCount":62},[],{"trials":2136,"activeCount":62},[],{"trials":2138,"activeCount":62},[],{"intervention":110,"totalTrials":123,"cells":2140},{"EARLY_PHASE1":2141,"PHASE1":2143,"PHASE2":2149,"PHASE3":2151,"PHASE4":2153,"NA":2155},{"trials":2142,"activeCount":62},[],{"trials":2144,"activeCount":62},[2145],{"nctId":101,"briefTitle":102,"status":103,"phases":2146,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":2147,"interventions":2148},[52],[18],[110,111,112,94],{"trials":2150,"activeCount":62},[],{"trials":2152,"activeCount":62},[],{"trials":2154,"activeCount":62},[],{"trials":2156,"activeCount":62},[],{"intervention":111,"totalTrials":123,"cells":2158},{"EARLY_PHASE1":2159,"PHASE1":2161,"PHASE2":2167,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2160,"activeCount":62},[],{"trials":2162,"activeCount":62},[2163],{"nctId":101,"briefTitle":102,"status":103,"phases":2164,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":2165,"interventions":2166},[52],[18],[110,111,112,94],{"trials":2168,"activeCount":62},[],{"trials":2170,"activeCount":62},[],{"trials":2172,"activeCount":62},[],{"trials":2174,"activeCount":62},[],{"intervention":112,"totalTrials":123,"cells":2176},{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2185,"PHASE3":2187,"PHASE4":2189,"NA":2191},{"trials":2178,"activeCount":62},[],{"trials":2180,"activeCount":62},[2181],{"nctId":101,"briefTitle":102,"status":103,"phases":2182,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":2183,"interventions":2184},[52],[18],[110,111,112,94],{"trials":2186,"activeCount":62},[],{"trials":2188,"activeCount":62},[],{"trials":2190,"activeCount":62},[],{"trials":2192,"activeCount":62},[],{"intervention":1354,"totalTrials":123,"cells":2194},{"EARLY_PHASE1":2195,"PHASE1":2197,"PHASE2":2203,"PHASE3":2205,"PHASE4":2207,"NA":2209},{"trials":2196,"activeCount":62},[],{"trials":2198,"activeCount":62},[2199],{"nctId":1346,"briefTitle":1347,"status":129,"phases":2200,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1196,"conditions":2201,"interventions":2202},[52],[1352],[433,1354],{"trials":2204,"activeCount":62},[],{"trials":2206,"activeCount":62},[],{"trials":2208,"activeCount":62},[],{"trials":2210,"activeCount":62},[],{"intervention":1502,"totalTrials":123,"cells":2212},{"EARLY_PHASE1":2213,"PHASE1":2215,"PHASE2":2221,"PHASE3":2223,"PHASE4":2225,"NA":2227},{"trials":2214,"activeCount":62},[],{"trials":2216,"activeCount":62},[2217],{"nctId":1496,"briefTitle":1497,"status":129,"phases":2218,"primaryCompletion":600,"completion":600,"start":1499,"enrollment":650,"conditions":2219,"interventions":2220},[52],[15],[1502,1441,1503,1504],{"trials":2222,"activeCount":62},[],{"trials":2224,"activeCount":62},[],{"trials":2226,"activeCount":62},[],{"trials":2228,"activeCount":62},[],{"intervention":2230,"totalTrials":123,"cells":2231},"Tiotropium",{"EARLY_PHASE1":2232,"PHASE1":2234,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2233,"activeCount":62},[],{"trials":2235,"activeCount":62},[2236],{"nctId":2237,"briefTitle":2238,"status":129,"phases":2239,"primaryCompletion":2240,"completion":2240,"start":2241,"enrollment":363,"conditions":2242,"interventions":2243},"NCT03945344","Effect of Charcoal on Gastrointestinal Absorption of Tiotropium",[52],"2019-06-19","2019-05-27",[31],[2230,2230],{"trials":2245,"activeCount":62},[],{"trials":2247,"activeCount":62},[],{"trials":2249,"activeCount":62},[],{"trials":2251,"activeCount":62},[],{"intervention":2253,"totalTrials":123,"cells":2254},"salmeterol \u002F fluticasone propionate",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2272},{"trials":2256,"activeCount":62},[],{"trials":2258,"activeCount":62},[2259],{"nctId":2260,"briefTitle":2261,"status":129,"phases":2262,"primaryCompletion":1436,"completion":1436,"start":2263,"enrollment":363,"conditions":2264,"interventions":2265},"NCT01564199","Phase I Pharmacokinetic Study (SALBLOCK)",[52],"2012-04",[31],[2253],{"trials":2267,"activeCount":62},[],{"trials":2269,"activeCount":62},[],{"trials":2271,"activeCount":62},[],{"trials":2273,"activeCount":62},[],{"intervention":848,"totalTrials":123,"cells":2275},{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2284,"PHASE3":2286,"PHASE4":2288,"NA":2290},{"trials":2277,"activeCount":62},[],{"trials":2279,"activeCount":62},[2280],{"nctId":840,"briefTitle":841,"status":129,"phases":2281,"primaryCompletion":843,"completion":843,"start":844,"enrollment":845,"conditions":2282,"interventions":2283},[52],[23],[848,833,433],{"trials":2285,"activeCount":62},[],{"trials":2287,"activeCount":62},[],{"trials":2289,"activeCount":62},[],{"trials":2291,"activeCount":62},[],{"intervention":2293,"totalTrials":123,"cells":2294},"ODM-106",{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2306,"PHASE3":2308,"PHASE4":2310,"NA":2312},{"trials":2296,"activeCount":62},[],{"trials":2298,"activeCount":62},[2299],{"nctId":2300,"briefTitle":2301,"status":129,"phases":2302,"primaryCompletion":2303,"completion":1472,"start":1946,"enrollment":1059,"conditions":2304,"interventions":2305},"NCT02393950","Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers",[52],"2015-10",[31],[2293],{"trials":2307,"activeCount":62},[],{"trials":2309,"activeCount":62},[],{"trials":2311,"activeCount":62},[],{"trials":2313,"activeCount":62},[],{"intervention":1476,"totalTrials":123,"cells":2315},{"EARLY_PHASE1":2316,"PHASE1":2318,"PHASE2":2324,"PHASE3":2326,"PHASE4":2328,"NA":2330},{"trials":2317,"activeCount":62},[],{"trials":2319,"activeCount":62},[2320],{"nctId":1469,"briefTitle":1470,"status":129,"phases":2321,"primaryCompletion":1472,"completion":1472,"start":1473,"enrollment":363,"conditions":2322,"interventions":2323},[52],[15],[1476,1439],{"trials":2325,"activeCount":62},[],{"trials":2327,"activeCount":62},[],{"trials":2329,"activeCount":62},[],{"trials":2331,"activeCount":62},[],{"intervention":366,"totalTrials":123,"cells":2333},{"EARLY_PHASE1":2334,"PHASE1":2336,"PHASE2":2342,"PHASE3":2344,"PHASE4":2346,"NA":2348},{"trials":2335,"activeCount":62},[],{"trials":2337,"activeCount":62},[2338],{"nctId":358,"briefTitle":359,"status":129,"phases":2339,"primaryCompletion":361,"completion":361,"start":362,"enrollment":363,"conditions":2340,"interventions":2341},[52],[21],[351,366],{"trials":2343,"activeCount":62},[],{"trials":2345,"activeCount":62},[],{"trials":2347,"activeCount":62},[],{"trials":2349,"activeCount":62},[],{"intervention":2351,"totalTrials":123,"cells":2352},"ODM-102",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2367,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2354,"activeCount":62},[],{"trials":2356,"activeCount":62},[2357],{"nctId":2358,"briefTitle":2359,"status":129,"phases":2360,"primaryCompletion":2361,"completion":2362,"start":2363,"enrollment":2364,"conditions":2365,"interventions":2366},"NCT01839019","Safety and Tolerability Study With Single Ascending Doses of ODM-102",[52],"2013-06","2013-08","2013-04",22,[23],[2351],{"trials":2368,"activeCount":62},[],{"trials":2370,"activeCount":62},[],{"trials":2372,"activeCount":62},[],{"trials":2374,"activeCount":62},[],{"intervention":2376,"totalTrials":123,"cells":2377},"ODM 203",{"EARLY_PHASE1":2378,"PHASE1":2380,"PHASE2":2390,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2379,"activeCount":62},[],{"trials":2381,"activeCount":62},[2382],{"nctId":2383,"briefTitle":2384,"status":129,"phases":2385,"primaryCompletion":2386,"completion":2386,"start":2387,"enrollment":375,"conditions":2388,"interventions":2389},"NCT02264418","Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours",[52],"2019-05","2014-09-18",[73],[2376,2376],{"trials":2391,"activeCount":62},[],{"trials":2393,"activeCount":62},[],{"trials":2395,"activeCount":62},[],{"trials":2397,"activeCount":62},[],{"intervention":2399,"totalTrials":123,"cells":2400},"ODM-201 Tablet A",{"EARLY_PHASE1":2401,"PHASE1":2403,"PHASE2":2416,"PHASE3":2418,"PHASE4":2420,"NA":2422},{"trials":2402,"activeCount":62},[],{"trials":2404,"activeCount":62},[2405],{"nctId":2406,"briefTitle":2407,"status":129,"phases":2408,"primaryCompletion":2362,"completion":2409,"start":2410,"enrollment":2411,"conditions":2412,"interventions":2413},"NCT01784757","Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer",[52],"2020-12","2013-03",30,[26],[2399,2414,2415],"ODM-201 Tablet B","ODM-201 capsule formulation",{"trials":2417,"activeCount":62},[],{"trials":2419,"activeCount":62},[],{"trials":2421,"activeCount":62},[],{"trials":2423,"activeCount":62},[],{"intervention":2414,"totalTrials":123,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2434,"PHASE3":2436,"PHASE4":2438,"NA":2440},{"trials":2427,"activeCount":62},[],{"trials":2429,"activeCount":62},[2430],{"nctId":2406,"briefTitle":2407,"status":129,"phases":2431,"primaryCompletion":2362,"completion":2409,"start":2410,"enrollment":2411,"conditions":2432,"interventions":2433},[52],[26],[2399,2414,2415],{"trials":2435,"activeCount":62},[],{"trials":2437,"activeCount":62},[],{"trials":2439,"activeCount":62},[],{"trials":2441,"activeCount":62},[],{"intervention":2415,"totalTrials":123,"cells":2443},{"EARLY_PHASE1":2444,"PHASE1":2446,"PHASE2":2452,"PHASE3":2454,"PHASE4":2456,"NA":2458},{"trials":2445,"activeCount":62},[],{"trials":2447,"activeCount":62},[2448],{"nctId":2406,"briefTitle":2407,"status":129,"phases":2449,"primaryCompletion":2362,"completion":2409,"start":2410,"enrollment":2411,"conditions":2450,"interventions":2451},[52],[26],[2399,2414,2415],{"trials":2453,"activeCount":62},[],{"trials":2455,"activeCount":62},[],{"trials":2457,"activeCount":62},[],{"trials":2459,"activeCount":62},[],{"intervention":2461,"totalTrials":123,"cells":2462},"Budesonide\u002Fformoterol capsule.",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2476,"PHASE3":2478,"PHASE4":2480,"NA":2482},{"trials":2464,"activeCount":62},[],{"trials":2466,"activeCount":62},[2467],{"nctId":2468,"briefTitle":2469,"status":129,"phases":2470,"primaryCompletion":2471,"completion":2471,"start":2472,"enrollment":363,"conditions":2473,"interventions":2474},"NCT01423305","Phase I Pharmacokinetic Study (BF-BLOCK)",[52],"2011-10","2011-08",[15],[2461,2475],"Budesonide\u002Fformoterol capsule for oral adm.",{"trials":2477,"activeCount":62},[],{"trials":2479,"activeCount":62},[],{"trials":2481,"activeCount":62},[],{"trials":2483,"activeCount":62},[],{"intervention":2475,"totalTrials":123,"cells":2485},{"EARLY_PHASE1":2486,"PHASE1":2488,"PHASE2":2494,"PHASE3":2496,"PHASE4":2498,"NA":2500},{"trials":2487,"activeCount":62},[],{"trials":2489,"activeCount":62},[2490],{"nctId":2468,"briefTitle":2469,"status":129,"phases":2491,"primaryCompletion":2471,"completion":2471,"start":2472,"enrollment":363,"conditions":2492,"interventions":2493},[52],[15],[2461,2475],{"trials":2495,"activeCount":62},[],{"trials":2497,"activeCount":62},[],{"trials":2499,"activeCount":62},[],{"trials":2501,"activeCount":62},[],{"intervention":1449,"totalTrials":123,"cells":2503},{"EARLY_PHASE1":2504,"PHASE1":2506,"PHASE2":2512,"PHASE3":2514,"PHASE4":2516,"NA":2518},{"trials":2505,"activeCount":62},[],{"trials":2507,"activeCount":62},[2508],{"nctId":1443,"briefTitle":1444,"status":129,"phases":2509,"primaryCompletion":1446,"completion":1446,"start":383,"enrollment":1230,"conditions":2510,"interventions":2511},[52],[15],[1449,1426],{"trials":2513,"activeCount":62},[],{"trials":2515,"activeCount":62},[],{"trials":2517,"activeCount":62},[],{"trials":2519,"activeCount":62},[],{"intervention":1416,"totalTrials":123,"cells":2521},{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2530,"PHASE3":2532,"PHASE4":2534,"NA":2536},{"trials":2523,"activeCount":62},[],{"trials":2525,"activeCount":62},[2526],{"nctId":1409,"briefTitle":1410,"status":129,"phases":2527,"primaryCompletion":740,"completion":1412,"start":1413,"enrollment":19,"conditions":2528,"interventions":2529},[52],[18],[1396,1416],{"trials":2531,"activeCount":62},[],{"trials":2533,"activeCount":62},[],{"trials":2535,"activeCount":62},[],{"trials":2537,"activeCount":62},[],{"intervention":2539,"totalTrials":123,"cells":2540},"Indacaterol\u002Fglycopyrronium",{"EARLY_PHASE1":2541,"PHASE1":2543,"PHASE2":2553,"PHASE3":2555,"PHASE4":2557,"NA":2559},{"trials":2542,"activeCount":62},[],{"trials":2544,"activeCount":62},[2545],{"nctId":2546,"briefTitle":2547,"status":129,"phases":2548,"primaryCompletion":2549,"completion":2549,"start":2550,"enrollment":1314,"conditions":2551,"interventions":2552},"NCT05288075","Study to Compare Relative Bioavailability of 3 Indacaterol\u002FGlycopyrronium Test Products and Reference Product",[52],"2022-06-27","2022-02-28",[23],[2539],{"trials":2554,"activeCount":62},[],{"trials":2556,"activeCount":62},[],{"trials":2558,"activeCount":62},[],{"trials":2560,"activeCount":62},[],{"intervention":726,"totalTrials":123,"cells":2562},{"EARLY_PHASE1":2563,"PHASE1":2569,"PHASE2":2571,"PHASE3":2573,"PHASE4":2575,"NA":2577},{"trials":2564,"activeCount":62},[2565],{"nctId":721,"briefTitle":722,"status":129,"phases":2566,"primaryCompletion":240,"completion":240,"start":301,"enrollment":11,"conditions":2567,"interventions":2568},[51],[18],[726,715],{"trials":2570,"activeCount":62},[],{"trials":2572,"activeCount":62},[],{"trials":2574,"activeCount":62},[],{"trials":2576,"activeCount":62},[],{"trials":2578,"activeCount":62},[],{"intervention":2580,"totalTrials":123,"cells":2581},"Budesonide-Formoterol",{"EARLY_PHASE1":2582,"PHASE1":2584,"PHASE2":2586,"PHASE3":2588,"PHASE4":2590,"NA":2592},{"trials":2583,"activeCount":62},[],{"trials":2585,"activeCount":62},[],{"trials":2587,"activeCount":62},[],{"trials":2589,"activeCount":62},[],{"trials":2591,"activeCount":62},[],{"trials":2593,"activeCount":62},[2594],{"nctId":2595,"briefTitle":2596,"status":103,"phases":2597,"primaryCompletion":2598,"completion":2598,"start":2599,"enrollment":2600,"conditions":2601,"interventions":2603},"NCT04663386","Switch of Budesonide-formoterol Dry Powder Inhalers at Pharmacy in Norway",[],"2021-09-14","2020-12-10",29,[15,2602],"COPD",[2580],{"intervention":2605,"totalTrials":123,"cells":2606},"Budesonide",{"EARLY_PHASE1":2607,"PHASE1":2609,"PHASE2":2611,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2608,"activeCount":62},[],{"trials":2610,"activeCount":62},[],{"trials":2612,"activeCount":62},[],{"trials":2614,"activeCount":62},[],{"trials":2616,"activeCount":62},[],{"trials":2618,"activeCount":62},[2619],{"nctId":2620,"briefTitle":2621,"status":129,"phases":2622,"primaryCompletion":1730,"completion":919,"start":2471,"enrollment":2623,"conditions":2624,"interventions":2625},"NCT01457716","Pharmacokinetic Pilot Study on Budesonide\u002FFormoterol",[56],17,[18],[2605,2626],"Formoterol",{"intervention":2626,"totalTrials":123,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2633,"PHASE3":2635,"PHASE4":2637,"NA":2639},{"trials":2630,"activeCount":62},[],{"trials":2632,"activeCount":62},[],{"trials":2634,"activeCount":62},[],{"trials":2636,"activeCount":62},[],{"trials":2638,"activeCount":62},[],{"trials":2640,"activeCount":62},[2641],{"nctId":2620,"briefTitle":2621,"status":129,"phases":2642,"primaryCompletion":1730,"completion":919,"start":2471,"enrollment":2623,"conditions":2643,"interventions":2644},[56],[18],[2605,2626]]